Christopher Flint O Brien Net Worth

The estimated Net Worth of Christopher Flint O Brien is at least $18.8 Million dollars as of 5 February 2018. Christopher Brien owns over 2,613 units of Neurocrine Biosciences stock worth over $6,597,036 and over the last 19 years Christopher sold NBIX stock worth over $12,168,593.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Christopher Brien NBIX stock SEC Form 4 insiders trading

Christopher has made over 47 trades of the Neurocrine Biosciences stock since 2013, according to the Form 4 filled with the SEC. Most recently Christopher sold 2,613 units of NBIX stock worth $217,349 on 5 February 2018.

The largest trade Christopher's ever made was exercising 105,634 units of Neurocrine Biosciences stock on 18 May 2017 worth over $671,832. On average, Christopher trades about 11,263 units every 27 days since 2005. As of 5 February 2018 Christopher still owns at least 54,310 units of Neurocrine Biosciences stock.

You can see the complete history of Christopher Brien stock trades at the bottom of the page.

What's Christopher Brien's mailing address?

Christopher's mailing address filed with the SEC is NEUROCRINE BIOSCIENCES, INC., 12790 EL CAMINO REAL, SAN DIEGO, CA, 92130.

Insiders trading at Neurocrine Biosciences

Over the last 22 years, insiders at Neurocrine Biosciences have traded over $159,913,426 worth of Neurocrine Biosciences stock and bought 103,400 units worth $589,660 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog..., and Richard F Pops. On average, Neurocrine Biosciences executives and independent directors trade stock every 8 days with the average trade being worth of $1,567,813. The most recent stock trade was executed by William H Rastetter on 15 August 2024, trading 14,250 units of NBIX stock currently worth $2,090,333.

What does Neurocrine Biosciences do?

neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders

Complete history of Christopher Brien stock trades at Neurocrine Biosciences

Neurocrine Biosciences executives and stock owners

Neurocrine Biosciences executives and other stock owners filed with the SEC include:

• Kevin Gorman,
  Chief Executive Officer, Director
• Matthew Abernethy,
  Chief Financial Officer
• Eric Benevich,
  Chief Commercial Officer
• Eiry Roberts,
  Chief Medical Officer
• Haig Bozigian,
  Chief Development Officer
• Kyle Gano,
  Chief Business Development and Strategy Officer
• Dimitri Grigoriadis,
  Chief Research Officer
• Dr. Kevin C. Gorman Ph.D.,
  CEO & Director
• Dr. Eiry Wyn Roberts,
  Chief Medical Officer
• Leslie Norwalk,
  Independent Director
• Matthew C. Abernethy,
  Chief Financial Officer
• Eric S. Benevich,
  Chief Commercial Officer
• Kyle W. Gano,
  Chief Bus. Devel. and Strategy Officer
• William Rastetter,
  Independent Chairman of the Board
• Stephen Sherwin,
  Independent Director
• Richard Pops,
  Independent Director
• George Morrow,
  Independent Director
• Gary Lyons,
  Independent Director
• Todd Tushla,
  Investor Relations
• Julie Cooke,
  Chief Human Resource Officer
• Shalini Sharp,
  Independent Director
• Darin Lippoldt,
  Chief Legal Officer and Corporate Secretary
• Malcolm Lloyd-Smith,
  Chief Regulatory Officer
• David Boyer,
  Chief Corporate Affairs Officer
• Julie S. Cooke,
  Chief HR Officer
• Darin M. Lippoldt,
  Chief Legal Officer & Corp. Sec.
• Jane Sorensen,
  Head of Investor Relations
• Dr. Jude Onyia Ph.D.,
  Chief Scientific Officer
• Dr. Dimitri E. Grigoriadis,
  Chief Research Officer
• Matt Abernethy,
  Chief Financial Officer
• Corinne H Nevinny,
  Director
• Christopher Flint O Brien,
  Sr. VP & Chief Medical Officer
• Joseph A Mollica,
  Director
• David Alexandre C Gros,
  President & COO
• Alfred Sandrock,
  Director
• Christine A Poon,
  Director
• Wylie W Vale,
  Director
• Timothy Coughlin,
  VP and Chief Financial Officer
• Jensen Margaret E Valeur,
  Senior VP and General Counsel
• Partners L P/Ilbiotechnolog...,
  
• Johanna Mercier,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Partners L P/Ilbiotechnolog...,
  
• Henry Pan,
  Executive VP and CMO
• Wendall Wierenga,
  EVP, Research & Development
• Richard J Ranieri,
  Sr. VP, Human Resources
• Thomas Mitchell W,
  Director
• Ingrid Delaet,
  Chief Regulatory Officer
• Paul W Hawran,
  Executive VP and CFO
• Paul J Conlon,
  Vice President Research (Biol)
• Lawrence Steinman,
  Director
• John Saunders,
  Vice President Research (Chem)
• Robert J Little,
  SVP, Commercial Operations
• D Bruce Campbell,
  Senior Vice President
• Jude Onyia,
  Chief Scientific Officer